Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Muhammad Mustafa

Cardiovascular Disease Winter Haven, FL Medical Doctor

NPI 1932480688 CMS profile 315250

500 E Central Ave, Winter Haven, FL 33880

Open in the dashboard

General payments

$23,939

475 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Muhammad Mustafa of Winter Haven, FL is reported in the CMS Open Payments database as having received $23,939 across 475 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,422 73
2024 General $1,056 48
2023 General $1,482 66
2022 General $1,156 58
2021 General $1,474 78
2020 General $5,628 73
2019 General $11,722 79

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Muhammad Mustafa
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Muhammad Mustafa were reported at $1,422. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Muhammad Mustafa Cardiovascular Disease median Middle half National median
2019 $11,722 $450 $127–$1,392 $163
2020 $5,628 $242 $77–$751 $114
2021 $1,474 $335 $101–$1,037 $132
2022 $1,156 $395 $121–$1,211 $149
2023 $1,482 $443 $136–$1,283 $160
2024 $1,056 $450 $136–$1,323 $164
2025 $1,422 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novartis Pharmaceuticals Corporation $13,015 49 payments
  2. Coala Life Inc $2,714 3 payments
  3. Boston Scientific Corporation $1,417 68 payments
  4. Amgen Inc. $1,057 54 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $853 49 payments
  6. AstraZeneca Pharmaceuticals LP $742 38 payments
  7. Merck Sharp & Dohme Corporation $681 35 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $606 25 payments
  9. Pfizer Inc. $483 27 payments
  10. E.R. Squibb & Sons, L.L.C. $470 24 payments
  11. Other $1,902 103 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,928 7 payments
  2. Food and Beverage $8,866 453 payments
  3. Consulting Fee $2,700 2 payments
  4. Travel and Lodging $289 6 payments
  5. Education $156 7 payments
Products named General payments · program years 2019–2025
  1. ENTRESTO $12,715 31 payments
  2. Coala Heart Monitor $2,714 3 payments
  3. Repatha $911 46 payments
  4. VERQUVO $681 35 payments
  5. FARXIGA $673 34 payments
  6. JARDIANCE $631 38 payments
  7. LifeVest $606 25 payments
  8. ELIQUIS Cardiovascular;Metabolic Disease $318 18 payments
  9. ELIQUIS Cardiovascular $310 16 payments
  10. LEQVIO $300 18 payments
  11. Other $4,687 251 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 52 drugs

Part D claims

6,701

Median for Cardiology: 2,533

Drug cost

$2,092,696

Median for Cardiology: $485,213

Branded share of claims

39.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 776 $765,641
Entresto Sacubitril/Valsartan Brand 554 $600,289
Jardiance Empagliflozin Brand 184 $183,677
Farxiga Dapagliflozin Propanediol Brand 149 $152,358
Repatha Sureclick Evolocumab Brand 222 $151,089
Xarelto Rivaroxaban Brand 126 $149,542
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 41 $11,306
Metoprolol Succinate Generic 641 $9,533
Praluent Pen Alirocumab Brand 15 $9,489
Vascepa Icosapent Ethyl Brand 17 $7,318

The 10 drugs with the highest cost, of 52 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 93 billing codes

Paid by Medicare

$634,532

Of which drugs: $1,545

Medicare patients

2,278

Average age 77

Services billed

11,193

1,183 women, 1,095 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 56%
Arthritis 56%
Ischemic heart disease 48%
Diabetes 42%
Atrial fibrillation 39%
Heart failure 36%
Depression 32%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 72 288 $1,497

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $148
$148 149 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $118
$118 184 —
Repatha
  • Amgen Inc. $115
$115 222 —
ELIQUIS
  • PFIZER INC. $44
  • E.R. Squibb & Sons, L.L.C. $44
$88 776 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $46
$46 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

475 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record